**ANTIMICROBIAL SUSCEPTIBILITY TRENDS AMONG VIRIDAN STREPTOCOCCI ISOLATES FROM CASES OF ENDOCARDITIS FROM 2011 – 2012**

Prabhu N##, Jeyaseelan Senthinath T*, Joseph Pushpa Innocent D**, Lalitha MK***

*Department of Microbiology and Health Science Research, Chennai Medical College Hospital and Research Centre, Tiruchirapalli – 621 105, India.

**Department of Microbiology, Karpaga Vinayaga Institute of Medical Sciences and Research Institute, Madhuranthagam, Rancheepuram, India.

***Department of Microbiology, Madras Medical Mission, Mogappair, Chennai, India.

**ARTICLE INFO**

**Corresponding Author:** Prabhu N,
Department of Microbiology and Health Science Research, Chennai Medical College Hospital and Research Centre, Tiruchirapalli – 621 105, India.

**Keywords:** Viridans streptococci – endocarditis – antibiogram

**ABSTRACT**

To determine the changes found in antimicrobial resistant character occurred among viridans groups of streptococci, this study examined 30 viridans group streptococci isolated from infective endocarditis patients. The isolation patterns revealed based on biochemical identification as four viridans streptococcal species groups – *mitis, mutans, salivarius* and *sanguinis*. Resistance rates of the isolates were as follows, Penicillin – 2; Clindamycin – 2; Erythromycin – 5; Azithromycin – 10; Vancomycin – 4; Levofloxacin – 1 and Ciprofloxacin – 2.

**INTRODUCTION**

The observation of Bacteremia episodes due to viridans group of streptococci found 20 – 40% in neutropenic patients 1,2,3,4 and 30 – 40% of infective endocarditis cases 5. In hematologic patients, fluoroquinolones are used as antibacterial prophylaxis agents during the neutropenic period after haematopoietic stem cell transplantation or chemotherapy alone 6. Many case studies highlighted the episodes of bacteremia with fluoroquinolone resistant viridans group streptococci during fluoroquinolone prophylaxis 7,8. Previous study reported 16% rate of this problem with fluoroquinolone resistant viridans group streptococci during Levofloxacin prophylaxis in hematology patients undergoing autologous stem cell transplantation 9. In recent years, several case reports of infective endocarditis due to penicillin resistant viridans group streptococci have been published 10-13. By taking the research of above said as reference, we retrospectively examined antimicrobial susceptibility trends, including fluoroquinolone susceptibility, in a collection of viridans group streptococcal isolates spanning 5 years, to see if changes found in antimicrobial resistance had occurred.

**MATERIALS & METHODS**

The selected blood samples from bacterial endocarditis patients have been collected from tertiary care hospitals of Thanjavur district with proper institutional ethical clearance and processed bacteriologically. The cultural patterns were biochemically identified and classified according to the criteria set forth by Focklam 14. 30 isolates collected from 2001 – 2005 were included in this study. These isolated organism have clinically relevance from the antimicrobial susceptibility perspective because they are of proven pathogenic potential in immuno competent hosts, MICs were determined by broth microdilution in cation adjusted Mueller Hinton broth supplemented with 2.5% lyesed horse blood and interpreted according to NCCLS guidelines 15,16. The concentration ranges tested were 0.125 to 128 g/ml (in doubling dilutions) for Pencillin, Clindamycin, Erythromycin, Azithromycin, Vancomycin, Levofloxacin, Ciprofloxacin. Till now NCCLS has not published susceptibility break points for quinolone – Ciprofloxacin included in this study.

**RESULTS & DISCUSSION**

Due to the initial identification data of many of the isolated, they were biochemically identified and classified into 4 viridans streptococcal species groups like *mitis, mutans, salivarius* and *sanguinis*. The confirmation of eh analysis is mainly through the performance tests on commonly used reagents. Streptococcus mitis is confirmed by optocin negative (resistant) on blood agar whereas *S. mutans* is optocin positive (susceptible).  

Among the isolates from 2001 – 2005, monobacterial isolation found in 12 cases (n=30) and polybacterial found in 19 cases and one found to be lost. In monobacterial analysis, *S. mitis* place top in 7 cases followed by *S. mutans, S. salivarius* and *S. sanguinis* in 2, 1 and 2 cases respectively. Among polybacterial studies (n=19), *S. mitis* and *S. mutans* mixture is in top of 10 cases followed by *S. mitis, S. mutans* and *S. salivarius* mixture, *S. mitis* and *S. sanguinis* mixture and *S. mitis, S. mutans* and *S. sanguinis* in 4, 2 and 3 respectively.
In isolates from 2011 – 2012, high rates of resistance were measured to Azithromycin (33%), Erythromycin (17%) and Vancomycin (13%). The lowest rates of non susceptibility were those to Ciprofloxacin (7%), Clindamycin (7%), Levofloxacin (3%) and Penicillin (7%). In this study, higher MIC were found for Ciprofloxacin (8 g/ml) and Levofloxacin (8 g/ml) supported some other studies. In contrast, the level of penicillin non susceptibility among the isolates (3%) was lower than the report in recent surveillance blood culture studies. Two of our isolates (one of S. mitis and one of S sanguinis) were penicillin non susceptible. The level of Azithromycin (33%) and Erythromycin (17%) resistancy among isolates in our study was comparable to previous studies. For the four vancomycin resistance viridans group streptococci isolates in the present investigation, the MICs were 2 g/ml and within the margin of the assay. There have been previous reports of viridans group streptococci for which vancomycin MICs were slightly elevated. There are some limitations in our study,
1. Sample size is small, so did not provide the power to detect statistical significance differences.
2. Viridans group of streptococci isolates were from tertiary care centre also may not be reflective of endocarditis isolates seen in community hospital.
3. The isolates from patients population include in this study are recovered may influence antimicrobial susceptibility patterns, isolated from endocarditis patients may not reflect the fluoroquinoneo – ciprofloxacin susceptible pattern. Some studies showed the trend to reducing susceptibility to ciprofloxacin in patients with a diagnosis of cancer verses those without such diagnosis.
4. The antimicrobial therapeutical history of these patients was unknown, a needful factor which may have influenced antimicrobial susceptibility.
5. Not all viridans group streptococcal strains were archived from endocarditis patients diagnosed during the time period of this study resulting in the level of non susceptibility reported in the context of these limitations.
6. Larger prospective surveillance studies are needed to monitor antimicrobial resistance in viridans group streptococci.

From defined patient populations such as neutropenic hematolgy and endocarditis patients. This is one of the novel studies of reporting antimicrobial susceptibility patterns of viridans group of streptococci based on clinical diagnosis. From this study, we come to conclusion that increasing levels of antimicrobial resistance could impact the rate of bacteremia with viridans group streptococci in neutropenic patients receiving fluoroquinone prophylaxis and may not influence antimicrobial prevention and management of infective endocarditis.

REFERENCES


